Evaluation the effect of co-enzyme Q10 in patients with thalassemia major

Evaluation the effect of co-enzyme Q10 supplementation on inhibition of ferroptosis in patients with thalassemia major referred to Shahrekord Hajer Hospital

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221211056777N1

Enrollment

Registered

2023-01-22

Start date

2023-03-02

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thalassemia major. Beta thalassemia

Interventions

50 patients with thalassemia major are selected. The laboratory parameters (superoxide dismutase (SOD), catalase and glutathione peroxidase, ferritin, hemoglobin, ESR and CRP) will be checked by ELISA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient with thalassemia major

Exclusion criteria

Exclusion criteria: Non-cooperation of the patient The presence of side effects People who suffer from infection and inflammation. Death of the patient

Design outcomes

Primary

Measure	Time frame
The level of superoxide dismutase, catalase and peroxidase enzymes and ferritin serum level. ESR, CRP. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: ELISA test kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShima Rahmati

Shahre-kord University of Medical Sciences

shimarahmati1987@gmail.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026